Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure

Circulation Journal

Volumn 69, Issue 5, 2005, Pages 596-602

  Mori, Tatsuhiko ^a   Hayashi, Tetsuya ^a   Sohmiya, Koichi ^a   Okuda, Nobuaki ^a   Shimomura, Hiroaki ^a   Ohkita, Mamoru ^a   Matsumura, Yasuo ^a   Yoshiyama, Minora ^b   Yoshikawa, Junichi ^b   Kitaura, Yasushi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Beta blocker; Heart failure; Remodeling

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CANDESARTAN; CELIPROLOL; ISOPRENALINE; PHOSPHOLAMBAN; PROTEIN SERCA2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; OSMOTIC MINIPUMP; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CELIPROLOL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; MALE; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VENTRICULAR REMODELING;

EID: 21144469341     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.596     Document Type: Article

References (28)

1. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: Reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res 2001; 88: 654-658.
2. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-569.
3. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
4. Flesch M, Schiffer F, Zolk O, Pinto Y, Rosenkranz S, Hirth-Dietrich C, et al. Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy. Hypertension 1997; 30: 383-391.
5. Tada M. Calcium cycling proteins of the cardiac sarcoplasmic reticulum. Circ J 2003; 67: 729-737.
6. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101: 378-384.
7. Yasumura Y, Miyatake K, Okamoto H, Miyauchi T, Kawana M, Tsutamoto T, et al. Rational for the use of combination angiotensin-converting enzyme inhibition and angiotensin II receptor blocker therapy in heart failure. Circ J 2004; 68: 361-366.
8. Kubo H, Margulies KB, Piacentino V 3rd, Gaughan JP, Houser SR. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 2001; 104: 1012-1018.
9. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362: 767-771.
10. Hara Y, Hamada M, Shigematsu Y, Ohtsuka T, Ogimoto A, Higaki J. Effect of beta-blockers on insulin resistance in patients with dilated cariomyopathy. Circ J 2003; 67: 701-704.
11. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, et al. Celiprolol, a vasodilatory β-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the tranbsition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004; 110: 692-699.
12. Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon JY for the CELICARD group. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. Am J Cardiol 2000; 85: 1467-1471.
13. Teerlink JR, Pfeffer JM, Pfeffer MA. Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis. J Card Fail 1998; 4: 45-56.
14. Grosjean SA, Arstall MA, Mitchell RN, Klappacher GW, Kelly RA, Pfeffer MA, et al. Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. J Card Fail 1999; 5: 236-245.
15. Yoshiyama M, Takeuchi K, Hanatani A, Shimada T, Takemoto Y, Shimizu N, et al. Effect of cilazapril on ventricular remodeling assessed by Doppler-echocardiographic assessment and cardiac gene expression. Cardiovasc Drugs Ther 1998; 12: 57-70.
16. Gallego B, Arevalo MA, Flores O, Lopez-Novoa JM, Perez-Barriocanal F. Renal fibrosis in diabetic and aortic-constricted hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1823-R1829.
17. Takemoto M, Egashira K, Tomita H, Utsui M, Okamoto H, Kitabatake A, et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627.
18. Tsuchihashi H, Yokoyama H, Nagatomo T. Binding characteristics of 3H-CGP12177 to beta-adrenoceptors in rat myocardial membranes. Jpn J Pharmacol 1989; 49: 11-19.
19. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. Int J Cancer 1998; 78: 661-666.
20. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991; 88: 7276-7280.
21. Movsesian MA, Karimi M, Green K, Jones LR. Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994; 90: 653-657.
22. Hayashi T, Ijiri Y, Toko H, Shimomura H, Okabe M, Terasaki F, et al. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy. Eur Heart J 2000; 21: 296-305.
23. Hayashi T, Mori T, Sohmiya K, Okada Y, Inamoto S, Okuda N, et al. Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus. J Cardiovasc Pharmacol 2003; 41: 923-929.
24. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 1994; 75: 105-113.
25. Grimm D, Holmer SR, Riegger GA, Kromer EP. Effects of beta-receptor blockade and angiotensin II type 1 receptor antagonism in isoproterenol-induced heart failure in the rat. Cardiovasc Pathol 1999; 8: 315-323.
26. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Beta-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101: 2103-2109.
27. Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H, et al. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 2003; 89: 1236-1242.
28. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-2825.